An official website of the United States government
Home
Name
Alpharadin
Alternate Names
Radium-223 chloride
Abbreviations
None
Category
Radiation
Subcategory
alpha radiation (radiopharmaceutical)
NSC Number
None
Primary Site
Bone metastases
Histology
None
Remarks
Alpharadin is currently in clinical trials for bone metastases from prostate and breast cancer. Radium 223 is a one targeting isoptope which kills cancer cells using alpha radiation. The FDA has recently granted Alpharadin Fast Track designation. Bayer Healthcare plans to submit for approval to regulatory authorities in Europe and the USA mid-year 2012. Code in Other Therapy field until approved.
Coding
This drug should be coded
